Insulin human / insulin isophane human

Humulin 70/30 improves glycemic control in adults with diabetes; pediatric safety/effectiveness are not established. Novolin 70/30 includes adults and pediatric patients with diabetes, without a numerical minimum age in its indication. Both contain 70% insulin isophane human (NPH) and 30% regular insulin human. Analog premixes and other ratios are outside these executable regimens.

Current FDA arrays list Humulin 70/30 vial/Pen and Novolin 70/30 as Over-the-counter. This federal product status does not establish local stock, state dispensing rules, suitability for self-initiation or automatic substitution. Use a clinician-directed diabetes plan.

Individualize using metabolic needs, glucose results and the glycemic goal. Changes in brand, type, strength, device, injection site, illness, activity, meals or renal/hepatic function require supervision and closer glucose monitoring. The total dose is the premix dose: do not add component percentages as extra insulin. Neither label supplies a universal units/kg initiation or maximum daily dose.

Humulin 70/30: inject approximately 30–45 minutes before a meal. Novolin 70/30: approximately 30 minutes before a meal; typically twice daily, each dose intended to cover two meals or a meal and snack. Do not generalize that schedule to every patient or analog premix. Obtain individualized missed-dose/meal-delay instructions; do not double a missed dose.

Subcutaneous abdomen, thigh, upper arm or buttocks; rotate within the region and avoid pits, thickened skin and amyloid lumps. Do not inject intravenously, use in a pump, mix with other insulin or dilute. Inspect after resuspension: uniformly white/cloudy without clumps, discoloration or particles; do not use clear or abnormal suspension. Vials require a U-100 insulin syringe.

Follow the full IFU and demonstrate technique before use.

Use a new needle, check the dose window rather than counting clicks, and remove the needle after injection. Pens are single-patient use even after needle changes; never reuse/share syringes. Do not refill a pen or improvise a syringe-transfer method; use only the device-specific IFU and obtain help if damaged or dose delivery is uncertain. A 60-unit device limit is not a maximum total daily dose.

During an episode of hypoglycemia, or hypersensitivity to the selected insulin product or its excipients. Other precautions and route prohibitions remain important even though separately classified.

The selected current Humulin 70/30 and Novolin 70/30 labels have no boxed warning. Life-threatening hypoglycemia, hypokalemia, allergy and device-related infection risks remain labeled precautions.

Hypoglycemia, local reactions, lipodystrophy/amyloid deposits, weight gain, edema, allergy and insulin antibodies can occur. Novolin also discusses transient refraction change, retinopathy worsening and painful neuropathy with rapid glucose improvement. Overdose can cause prolonged/recurrent hypoglycemia and low potassium. Oral glucose is appropriate for a mild low when able to swallow; seizure, loss of consciousness or inability to swallow needs emergency help and trained glucagon use. Do not give oral treatment to an unconscious person; recurrence can require prolonged observation and IV glucose.

Examples below do not replace a full medication review.

Renal/hepatic effects on premix PK/PD have not been studied; hypoglycemia risk increases and more frequent dose adjustment/glucose monitoring may be required. Older patients have increased risk with comorbid disease/polypharmacy. Do not assign a uniform percentage reduction.

Novolin’s pediatric dose is individualized using metabolic needs and frequent glucose checks. Humulin pediatric safety/effectiveness are not established. Do not transfer one product’s pediatric status or invent a common minimum age.

Decades of human-insulin data have not established an association with major adverse pregnancy outcomes, but do not prove absence of risk. Poor glycemic control has maternal/fetal risks, so monitor and individualize treatment. Exogenous human insulin enters milk; no adverse breastfed-infant reactions are reported in the cited literature, with limited milk-production data. Balance breastfeeding benefits, maternal need and risks.

Insulin promotes muscle/fat glucose uptake, inhibits hepatic glucose production, reduces lipolysis/proteolysis and supports protein synthesis. NPH extends the regular-insulin time course. Novolin label describes onset about 30 minutes and duration up to 24 hours. Humulin’s healthy-subject study describes onset about 50 minutes, peak effect about 3.5 hours and mean duration about 23 hours, with wide ranges. Absorption varies by site/activity and within the same patient.

Insulin uptake/degradation occurs mainly in liver, kidney, muscle and fat. Humulin study peak serum concentration averaged 2.2 hours; absorption-limited mixture kinetics prevent a reliable true terminal half-life estimate. Novolin’s label does not provide a numeric PK profile. Organ-impairment PK is unstudied; clinical glucose response determines adjustment.

Follow blood glucose and the individualized glycemic goal; increase checks during illness, exercise/diet changes, dose/product/site changes, pregnancy and renal/hepatic impairment. Review hypoglycemia awareness, injection sites, technique and dose delivery. Monitor potassium when at risk, and fluid retention/heart-failure symptoms with TZDs. Routine serum insulin levels are not used to titrate the selected labels.

Confirm the name, 70/30 ratio, U-100 concentration, prescribed units, meal timing and device before every injection. Maintain planned meals; obtain a written illness/missed-dose plan. Learn low-glucose symptoms, rescue and when to call emergency services; carry needed supplies. Avoid driving when low or until effects are understood; labels advise avoiding alcohol. Do not share devices, inject into abnormal skin or store with a needle attached. Use a sharps container and keep all supplies away from children.

Humulin 70/30 KwikPen: beige pen with brown dose knob/stripe, 3 mL containing 300 total units, U-100; five-pen carton NDC 0002-8803-59. Confirm the written label rather than color alone.

Selected Humulin and Novolin 70/30: 100 total units/mL, comprising 70 units/mL NPH and 30 units/mL regular human insulin; 10 mL vials (1,000 total units) and 3 mL pens (300 total units). Novolin also lists ReliOn packages. These are not U-200/U-500 products, analog 70/30 or a separately titratable pair of insulin ingredients. No other ratio/current availability is inferred.

Unopened refrigerated products: 2–8°C until expiry; never freeze, protect from heat/light. Humulin vial: up to 30°C, total 31-day room-temperature window including unopened time; opened vial may remain refrigerated within 31 days. Humulin KwikPen: total 10 days up to 30°C including unopened room time; in-use do not refrigerate. Novolin vial: unopened room window 42 days up to 25°C; opened 42 days up to 25°C, do not refrigerate. Novolin FlexPen: room window 28 days up to 30°C; in-use do not refrigerate. Apply the earliest relevant expiry/window and discard even with insulin remaining.